Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

Rhea-AI Summary

Vaxart, Inc. (NASDAQ: VXRT) will provide a business update and financial results for the year ending December 31, 2022, on March 15, 2023, after market close. A conference call with senior management is scheduled for the same day at 4:30 p.m. ET. Vaxart focuses on developing oral recombinant vaccines through a unique delivery system aimed at eliminating needle-stick injuries. Their product pipeline includes vaccines for coronavirus, norovirus, seasonal influenza, RSV, and HPV, along with existing intellectual property protections.

Conference call to begin at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednesday, March 15, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.

The conference call can be accessed using the following information:

Webcast: Click here
Date: Wednesday, March 15, 2023 – 4:30 p.m. ET
Domestic: 888-407-0832
International: 201-689-8433
Conference ID: 13735958

A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts
Vaxart Media Relations:		Investor Relations:
Mark Herr		Andrew Blazier
Vaxart, Inc.		FINN Partners
mherr@vaxart.com		IR@vaxart.com
(203) 517-8957		(646) 871-8486

FAQ

What financial results will Vaxart announce on March 15, 2023?

Vaxart will announce its financial results for the year ended December 31, 2022.

What is the time of Vaxart's conference call on March 15, 2023?

The conference call is scheduled for 4:30 p.m. ET.

How can I access Vaxart's conference call on March 15, 2023?

You can access the conference call via a webcast link provided in their press release.

What vaccines are currently being developed by Vaxart?

Vaxart is developing oral vaccines for coronavirus, norovirus, seasonal influenza, RSV, and HPV.